

Interim Safety Report

Date of the Report: May 09th, 2025

To: PfTBV Consortim

From: USTTB, Mali PfTBV Study Sponsor

Phase 1, Dose-Escalating, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Co-administration of Transmission-Blocking Vaccines (R0.6C-AIOH/ Matrix-MTM with Pfs230D1-EPA/Matrix-MTM) and individual comparators (R0.6C-AIOH/ Matrix-MTM ; ProC6C-AIOH/ Matrix-MTM and Pfs230D1-EPA/Matrix-MTM) against *Plasmodium falciparum* in Adults in Mali (TBVax2)

Current Protocol Version Number and Date: Version: Amendment 4.0, September 07th, 2022

Report prepared by: USTTB, Mali, Study Sponsor representative.

Status of protocol:

- ☐ Open to Accrual
- ☐ Closed to Accrual (provide explanation)
- ☒ Closed (permanently)
- ☐ Pause/Halt/Hold (provide explanation)
- ☐ Other (provide explanation)

Overview of study progress:

Consenting/Screening visits began on July 25th, 2022, with 152 people screened. A total of 10 subjects have been enrolled on the Pilot, Group #1 arms (1B,1C) and received their first injection on August 14th, 2022 and 100 subjects have enrolled on the Main, Group#2 arms (2A, 2B, 2C, 2D, 2E) and received their first injection on September 19-22, 2022 and also 5 subjects have been enrolled on the Main, Group#3 arms (3) and received their first injection on October 03,2022.

The pilot group (n=10) or low dose vaccine arm (1B,1C) received their first injection on August 14th, 2022, and their second injection on September 11th, 2022, and their third injection on October 09, 2022.

The main phase or high dose(n=100) vaccine arm (2A, 2B, 2C, 2D, 2E) received their first injection on September 19th - 22th 2022, and their second injection on October 17th - 31, 2022, and their third injection on November, 14th - 28, 2022.

The main group#3 (n=5) arms (3C) vaccine received their first injection on October 03,2022, and their second injection on October 31, 2022, and their third injection on March 20, 2023.

Number of Serious Adverse Events (SAEs) observed to date: 01

Blinded Adverse Event (AEs) Summary:

As of 7 April 2025 , which represents 967 days after first vaccination for the pilot (n=10) or 939 days after their second injection or 911 days after their third vaccination for pilot group 1, and 931 days after first vaccination or 903 days after their second injection or 875 days after their third vaccination for the main group 2 or high dose group (n=100), and 917 days after first vaccination or 889 days after their second or 749 days after their third vaccination injection for the main group Arm3 (n=5) there have been a total of 400 adverse events (AEs) reported among the 115 participants.

There were 123 AEs related to vaccination:

- Pilot [**30µg R0.6C-ALOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M**] 5 mild cases of injection site pain (two or occurred in the same participant) and 1 moderate case of neutropenia.
- Pilot [**Comparator Vaccine (Rabies) and normal saline**] 2 mild cases of injection site pain.

- Main (2A) [**100µg R0.6C-AIOH+50µg Matrix-M and normal saline**] 16 mild cases of injection site pain, 1 mild case of elevated Creatinine, 2 mild cases of leucopenia and 1 moderate case of injection site pain.
- Main (2B) [**100µg ProC6C-AIOH+50µg Matrix-M and normal saline**] 15 mild cases of injection site pain, 1 mild case of headache, 1 mild case of elevated ALT, 2 mild cases of leucopenia and 2 mild cases of neutropenia and 1 moderate case of leucopenia.
- Main(2C) [**40µg Pfs230D1-EPA+50µg Matrix-M and normal saline**] 20 mild cases of injection site pain (two or occurred in the same participant), 1 mild case injection site pruritus, 1 mild cases of headaches, 3 mild cases of leucopenia, 2 mild cases of neutropenia and 1 moderate case of injection site pain.
- Main(2D) [**100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)**] 14 mild cases of injection site pain (two or occurred in the same participant), 2 mild cases headaches, 2 mild cases of leucopenia and 2 mild cases of neutropenia.
- Main (2E) [**Comparator Vaccine (Rabies) and normal saline**] 6 mild cases of injection site pain (two or occurred in the same participant), 2 mild case of headache, 1 mild cases of leucopenia and 1 mild cases of neutropenia, 1 moderate case of leucopenia and 2 moderate cases of neutropenia.
- Main (Arm3C) [**40µg Pfs230D1-EPA+50µg Matrix-M**] 8 mild cases of injection site pain (two or occurred in the same participant), 1 mild case of headache, 1 mild cases of leucopenia and 1 mild cases of neutropenia and 1 moderate case of injection site pain.

One SAE has been reported to date.

SAE summary: On 12 June 2023, a 38-year-old female volunteer included in the TBVAx#2 study in Doneguebougou under the identifier MA-22-2060-V was received for an unscheduled visit for right inguinal pain radiating to the pelvis, vomiting, in whom our clinical examination found a history of inguinal hernia for more than 10 years, agitation, and a right inguinal mass that was hard and painful to palpation. Given the agitation and the intensity of the pain, suggesting a suspected strangulated inguinal hernia, we decided

to refer to the volunteer to the surgery department of the Point G Bamako, University Hospital for better management. The diagnosis of strangulated inguinal hernia was confirmed at the Point G, Bamako University Hospital surgery department. The volunteer was taken for emergency surgery for a strangulated inguinal hernia. The surgery went well, and the participant was feeling good. The severity of the SAE was Life-threatening, and it was not related to the study.

Issues and problems related to study conduct:

On Thursday, September 22, 2022, an episode of mistaken vaccination occurred. One volunteer assigned to Arm 2d (100 µg R0.6C-AIOH/25 µg Matrix-M co-administered with 20 µg Pfs230D1-EPA/27 µg Matrix-M™) mistakenly received vaccines from Arm 2a (100 µg R0.6C-AIOH/50 µg Matrix-M™ co-administered with Saline Control) instead. The error was detected within approximately 40 minutes during routine checks, and upon further investigation was found to be due to insufficient double-checking between the randomization sheet and the vaccine order form. For Arm 2a and Arm 2d, the first type of vaccine to be administered is identical, and the first type of vaccine was taken without identifying the second type of vaccine. The pharmacy team has since re-trained with a focus on verification of Arm assignments across the randomization sheet and pharmacy order forms.

The volunteer has remained blinded, with a plan to continue vaccinations on Arm 2a and this incident has been reported to the FMPOS ethical committee.

Lost to follow-up

6 subjects lost to follow up at the time of the report.

More detailed data are provided below in this Safety Report

Detailed Report

Phase 1, Dose-Escalating, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Co-administration of Transmission-Blocking Vaccines (R0.6C-AIOH/ Matrix-M™ with Pfs230D1-EPA/Matrix-M™) and individual comparators (R0.6C-AIOH/ Matrix-M™ ; ProC6C-AIOH/ Matrix-M™ and Pfs230D1-EPA/Matrix-M™) against *Plasmodium falciparum* in Adults in Mali (TBVax2)

Group	Arm	n= 115	Candidate vaccine dose and adjuvant combination
Pilot Phase			
	1B	n=5	3X (co-administration) 30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M
	1C	n=5	3x Comparator Vaccine (Rabies) and normal saline
Main Phase	2A	n=20	3x 100µg R0.6C-AIOH+50µg Matrix-M and normal saline
	2B	n=20	3x 100µg ProC6C-AIOH+50µg Matrix-M and normal saline
	2C	n=20	3X 40µg Pfs230D1-EPA+50µg Matrix-M and normal saline (Pfs230D1-EPA regimen may be adjusted based on ongoing clinical trial NCT05135273)
	2D	n=20	3X (co-administration) 100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA regimen may be adjusted based on ongoing clinical trial Protocol #2021/000105/MS/SESRS/CERS registered at: SRCTN13649456)
	2E	n=20	3x Comparator Vaccine (Rabies) and normal saline

Group	Arm	n= 115	Candidate vaccine dose and adjuvant combination
	3	n=5	3X 40µg Pfs230D1-EPA+50µg Matrix-M given on a 0, 1, and 6 month schedule (Pfs230D1-EPA regimen may be adjusted based on ongoing clinical trial NCT05135273)

Please note: Arm 1A has not been enrolled as sufficient safety was demonstrated by a prior trial (TBVax1). Also, based on preliminary results from the ongoing clinical trial NCT05135273, the dose of Pfs230D1-EPA has been selected as 20ug rather than 40ug as listed here for arms 2C, 2D, and 3.

Table 1: Enrollment Summary

Status	Products Received	Low Dose (Pilot)	Overall
Projected subject enrollment			
Subjects screened		152	
Subject rescreened		8	
Subjects not enrolled (Screen failed)		37	
Subjects enrolled		10	10
Subjects who received at least one vaccine		10	10
Subjects who withdrew post vaccination (lost to follow up)		0	0
Subjects who are on study		10	10
#Subjects received Vaccination #1	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	5	10
	Comparator Vaccine (Rabies) and normal saline	5	
#Subjects received Vaccination #2	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	5	10
	Comparator Vaccine (Rabies) and normal saline	5	
#Subjects received Vaccination #3	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	5	10
	Comparator Vaccine (Rabies) and normal saline	5	

Table 2: Enrollment Summary

Status	Products Received	High Dose (Main)	Overall
Subjects enrolled		10	10
Subjects who received at least one vaccine		10	10
Subjects who withdrew post vaccination (lost to follow up)		0	0
Subjects who are on study		101	101
#Subjects who received Vaccination #1	[Arm2A]100µg R0.6C- AlOH +50µg Matrix-M and normal saline	20	105
	[Arm2B]100µg ProC6C- AlOH +50µg Matrix-M and normal saline	20	
	[Arm2C] 40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	20	
	[Arm2D] 100µg R0.6C- AlOH +25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	20	
	[Arm2E] Comparator Vaccine (Rabies) and normal saline	20	
	[Arm3] 40µg Pfs230D1-EPA+50µg Matrix-M	5	
#Subjects who received Vaccination #2	[Arm2A]100µg R0.6C- AlOH +50µg Matrix-M and normal saline	20	104
	[Arm2B]100µg ProC6C- AlOH +50µg Matrix-M and normal saline	20	
	[Arm2C] 40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	20	

	[Arm2D] 100µg R0.6C- AlOH +25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19	
	[Arm2E] Comparator Vaccine (Rabies) and normal saline	20	
	[Arm3] 40µg Pfs230D1-EPA+50µg Matrix-M	5	
#Subjects who received Vaccination #3	[Arm2A]100µg R0.6C- AlOH +50µg Matrix-M and normal saline	20	103
	[Arm2B]100µg ProC6C- AlOH +50µg Matrix-M and normal saline	19	
	[Arm2C] 40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	20	
	[Arm2D] 100µg R0.6C- AlOH +25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19	
	[Arm2E] Comparator Vaccine (Rabies) and normal saline	20	
	[Arm3] 40µg Pfs230D1-EPA+50µg Matrix-M	5	

Table 3: Other reasons for not completing the study (Post Vaccination)

Subject ID	Arms	Product Received	Number of vaccines received	End of Study reason:
MA-22-1008-J	1B	30µg R0.6C-AlOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	3	Travel
MA-22-2004-K	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Travel
MA-22-2009-G	2B	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	2	Married
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	3	Travel
MA-22-2029-H	2E	Comparator Vaccine (Rabies) and normal saline	3	Travel
MA-22-2036-R	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Subject lost to follow up
MA-22-2037-S	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Subject lost to follow up
MA-22-2039-U	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Subject lost to follow up
MA-22-2043-A	2B	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	3	Subject lost to follow up
MA-22-2044-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	3	Subject lost to follow up
MA-22-2051-J	2A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	3	Travel

MA-22-2052-A	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Subject lost to follow up
MA-22-2053-D	2E	Comparator Vaccine (Rabies) and normal saline	3	Travel
MA-22-2064-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	3	Subject lost to follow up
MA-22-2066-M	2E	Comparator Vaccine (Rabies) and normal saline	3	Subject lost to follow up
MA-22-2072-F	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	3	Subject lost to follow up
MA-22-2075-K	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	3	Subject lost to follow up
MA-22-2078-A	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	3	Travelling to Exodus
MA-22-2086-Q	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	1	Travelling to Exodus
MA-22-2088-S	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	3	Subject lost to follow up
MA-22-2091-X	2E	Comparator Vaccine (Rabies) and normal saline	3	Travelling to Exodus
MA-22-2098-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	3	Married
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3	Travel

Table 4: Other reasons for not completing the study after enrollment (Pre-Vaccination)

Study ID	Arm	Status	Reason
SC-024	Main	Other	The sample size is closed
SC-057	Main	Other	The sample size is closed

Table 5: Demographic Summary

Category	Sub-category	Group#1 (Pilot)	Group#2 (Main)	Overall
		(N=10)	(N=105)	115
GENDER	Male	8(80%)	77(73%)	85(74%)
	Female	2(20%)	28(27%)	30(26%)
AGE	18-50 years	10(9%)	105(91%)	115(100%)
	Mean $\pm$ SD	34.4 $\pm$ 12.2	32.8 $\pm$ 9.24	32.9 $\pm$ 9.47
	Median	38.6	33.7	33.7
	Min, Max	18,49	18,49	18,49

Table 6: Local Reactogenicity Summary Pilot

Symptoms (Verbatim Term) Severity	Pilot - Group#1					
	Vax1(N=10)		Vax2(N=10)		Vax3(N=10)	
Arms (Product Received)	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline
Injection pain/tenderness						
None	10(100%)	10(100%)	8(80%)	10(100%)	7(70%)	8(80%)
Mild	0(0%)	0(0%)	2(20%)	0(0%)	3(30%)	2(20%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Injection erythema/redness						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Injection swelling						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Injection induration						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	

Symptoms (Verbatim Term) Severity	<i>Pilot - Group#1</i>					
	Vax1(N=10)		Vax2(N=10)		Vax3(N=10)	
Mild	0(0%)	0(0%)	10(100%)	10(100%)	10(100%)	10(100%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(100%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Injection pruritus						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	9(90%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(10%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Limitation of arm movement						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)

Table 7: Systemic AE Summary Pilot Group#1

Symptoms (Verbatim Term) Severity	Pilot - Group#1					
	Vax1(N=10)		Vax2(N=10)		Vax3(N=10)	
Arms (Product Received)	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline
Fever						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Headache						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Nausea/vomiting						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Diarrhea						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)

Symptoms (Verbatim Term) Severity	<i>Pilot - Group#1</i>					
	Vax1(N=10)		Vax2(N=10)		Vax3(N=10)	
Mild	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Abdominal pain						
None	10(100%)	10(100%)	10(100%)	10(100%)	9(99%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	1(1%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Fatigue						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Myalgia						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Arthralgia						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)

Symptoms (Verbatim Term) Severity	<i>Pilot - Group#1</i>					
	Vax1(N=10)		Vax2(N=10)		Vax3(N=10)	
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Urticaria						
None	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)	10(100%)
Mild	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Moderate	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Severe	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Potentially life Threatening	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)

Table 8: Local Reactogenicity Summary Main Group#2

[illegible]

Table 9: Systemic adverse event summary Main Group#2

[illegible]

Symptoms (Verbatim Term)		Severity

[illegible]

Table 10: AE listing by study group and arm, related to vaccine

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
Pilot					
	MA-22-1003-C	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1008-J	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1008-J	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	NEUTROPENIA	Grade 2 Moderate	Probably Related,
	MA-22-1009-K	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PRURITIS	Grade 1 Mild	Definitively/Related
Main					
	MA-22-2002-R	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2002-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2003-N	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2004-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2004-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2005-C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2005-C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2006-J	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2008-A	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	HEADACHES	Grade 1 Mild	Probably Related,
	MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2009-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
	MA-22-2010-M	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2011-Q	40µg Pfs230D1-EPA+ 25µg Matrix-M	ELEVATED CREATININE	Grade 1 Mild	Probably Related,
	MA-22-2012-E	40µg Pfs230D1-EPA+ 25µg Matrix-M	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2012-E	40µg Pfs230D1-EPA+ 25µg Matrix-M	LEUCOPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2014-S	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2015-D	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2015-D	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2018-V	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 2 Moderate	Definitively/Related
	MA-22-2018-V	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2019-W	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2019-W	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2019-W	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2020-B	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PRURITIS	Grade 1 Mild	Definitively/Related
	MA-22-2020-B	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2020-B	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	LEUCOPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2020-B	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2023-D	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2025-C	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2026-E	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	NEUTROPENIA	Grade 2 Moderate	Possibly -/Related
	MA-22-2026-E	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2027-F	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
	MA-22-2027-F	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	NEUTROPENIA	Grade 1 Mild	Probably Related,
	MA-22-2027-F	Comparator Vaccine (Rabies) and normal saline	LEUCOPENIA	Grade 2 Moderate	Probably Related,
	MA-22-2029-H	Comparator Vaccine (Rabies) and normal saline	HEADACHES	Grade 1 Mild	Probably Related,
	MA-22-2033-N	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Probably Related,
	MA-22-2033-N	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2034-P	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 2 Moderate	Definitively/Related
	MA-22-2036-R	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2036-R	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2037-S	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2038-T	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2038-T	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Probably Related,
	MA-22-2039-U	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2039-U	Comparator Vaccine (Rabies) and normal saline	HEADACHES	Grade 1 Mild	Probably Related,
	MA-22-2039-U	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2039-U	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2045-C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2046-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	NEUTROPENIA	Grade 2 Moderate	Probably Related,
	MA-22-2046-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Probably Related,
	MA-22-2047-E	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2048-F	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Probably Related,
	MA-22-2049-G	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2050-H	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	ELEVATED TRANSAMINASE	Grade 1 Mild	Probably Related,
	MA-22-2050-H	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2051-J	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
	MA-22-2051-J	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2053-D	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2056-H	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2056-H	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2060-V	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2060-V	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	HEADACHES	Grade 1 Mild	Definitively/Related
	MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2061-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2061-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2062-Q	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 2 Moderate	Possibly -/Related
	MA-22-2062-Q	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2064-A	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2065-R	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2065-R	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2067-S	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2067-S	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	LEUCOPENIA	Grade 1 Mild	Probably Related,
	MA-22-2067-S	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	NEUTROPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2069-E	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2069-E	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2070-G	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2070-G	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2070-G	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	HEADACHES	Grade 1 Mild	Probably Related,
	MA-22-2072-F	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2074-U	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2075-K	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
	MA-22-2076-C	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2076-C	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2077-K	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2077-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2078-A	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2078-A	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2080-M	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2080-M	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2082-R	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2082-R	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	LEUCOPENIA	Grade 1 Mild	Possibly -/Related
	MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2084-Z	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2085-T	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	HEADACHES	Grade 1 Mild	Probably Related,
	MA-22-2087-G	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2087-G	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2090-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2091-X	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2091-X	Comparator Vaccine (Rabies) and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2096-Q	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2098-U	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-2099-Z	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	NEUTROPENIA	Grade 1 Mild	Probably Related,
	MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	LEUCOPENIA	Grade 1 Mild	Probably Related,

Group	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
	MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 2 Moderate	Definitively/Related
	MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	HEADACHES	Grade 1 Mild	Possibly -/Related
	MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3102-B	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related
	MA-22-3102-B	40µg Pfs230D1-EPA+50µg Matrix-M	SITE INJECTION PAIN	Grade 1 Mild	Definitively/Related

Related means: Possibly related, probably related, definitively related

Table 11: AE listing by study arm, severity and relationship to vaccination

	Study ID	Products Received	AE Description	Severity	Relationship to Vaccine
Pilot					
	MA-22-1001-A	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
	MA-22-1001-A	Comparator Vaccine (Rabies) and normal saline	Sinobronchitis	Grade 1 Mild	Not Related,
	MA-22-1002-B	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1002-B	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1003-C	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Back pain	Grade 1 Mild	Unlikely Related
	MA-22-1003-C	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1003-C	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Leukopenia	Grade 1 Mild	Unlikely Related
	MA-22-1003-C	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Rhinitis	Grde2 Moderate	Not Related,
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1004-D	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site movement impairment	Grade 1 Mild	Not Related,
	MA-22-1005-E	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grde2 Moderate	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grade 1 Mild	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Otitis externa	Grade 1 Mild	Not Related,
	MA-22-1006-G	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade3 Severe	Not Related,

	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Neutropenia	Grde2 Moderate	Not Related,
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Leukopenia	Grade 1 Mild	Not Related,
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Neutropenia	Grde2 Moderate	Not Related,
	MA-22-1007-H	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Headaches	Grade 1 Mild	Not Related,
	MA-22-1008-J	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1008-J	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Neutropenia	Grde2 Moderate	Probably Related,
	MA-22-1008-J	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1009-K	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-1009-K	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grade 1 Mild	Not Related,
	MA-22-1009-K	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1009-K	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	Injection site pruritus	Grade 1 Mild	Definitively/Related
	MA-22-1010-M	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
Main	MA-22-2002-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-2002-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-2002-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Vomiting	Grade 1 Mild	Not Related,
	MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
	MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
	MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Leukocytosis	Grde2 Moderate	Not Related,

MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2003-N	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2004-K	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2004-K	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2004-K	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Wound	Grade 1 Mild	Not Related,
MA-22-2005-C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2005-C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2006-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2006-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2006-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Thrombocytopenia	Grde2 Moderate	Unlikely Related
MA-22-2007-P	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2007-P	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Probably Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Nausea	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Abdominal pain	Grade 1 Mild	Not Related,
MA-22-2008-A	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2009-G	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2009-G	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2010-M	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related

MA-22-2010-M	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2011-Q	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Elevated creatinine	Grade 1 Mild	Probably Related,
MA-22-2011-Q	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Unlikely Related
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Neutropenia	Grade 1 Mild	Possibly -/Related
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Leukopenia	Grade 1 Mild	Possibly -/Related
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Elevated ALT	Grade 1 Mild	Unlikely Related
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Dizziness	Grade 1 Mild	Not Related,
MA-22-2012-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2013-H	Comparator Vaccine (Rabies) and normal saline	Genital infection	Grde2 Moderate	Not Related,
MA-22-2013-H	Comparator Vaccine (Rabies) and normal saline	Elevated creatinine	Grade3 Severe	Not Related,
MA-22-2013-H	Comparator Vaccine (Rabies) and normal saline	Thermal burn	Grade 1 Mild	Not Related,
MA-22-2013-H	Comparator Vaccine (Rabies) and normal saline	Chest Pain	Grade 1 Mild	Not Related,
MA-22-2014-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2014-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Tonsillitis	Grade 1 Mild	Not Related,
MA-22-2014-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2014-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Aches	Grade 1 Mild	Not Related,
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,

MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Not Related,
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2015-D	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2016-T	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2017-U	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2017-U	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2017-U	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2018-V	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grde2 Moderate	Definitively/Related
MA-22-2018-V	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2018-V	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Sinobronchitis	Grade 1 Mild	Not Related,
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Possibly -/Related
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Abscess	Grade 1 Mild	Not Related,
MA-22-2019-W	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2020-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pruritus	Grade 1 Mild	Definitively/Related
MA-22-2020-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2020-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Possibly -/Related
MA-22-2020-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2021-Z	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grade 1 Mild	Unlikely Related

MA-22-2021-Z	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2021-Z	Comparator Vaccine (Rabies) and normal saline	Sinobronchitis	Grade 1 Mild	Not Related,
MA-22-2021-Z	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2021-Z	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2022-A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2022-A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2023-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2023-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2024-B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2024-B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2025-C	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Possibly -/Related
MA-22-2025-C	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site movement impairment	Grade 1 Mild	Not Related,
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grde2 Moderate	Possibly -/Related
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grade 1 Mild	Unlikely Related
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grade 1 Mild	Not Related,
MA-22-2026-E	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Probably Related,
MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grde2 Moderate	Probably Related,

MA-22-2027-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2028-G	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Probably Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Aches	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2029-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2030-J	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2030-J	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2031-K	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2031-K	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2031-K	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2032-M	Comparator Vaccine (Rabies) and normal saline	Sinobronchitis	Grade 1 Mild	Not Related,
MA-22-2032-M	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site movement impairment	Grade 1 Mild	Not Related,
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Sinobronchitis	Grade 1 Mild	Not Related,
MA-22-2033-N	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,

MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grde2 Moderate	Definitively/Related
MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Osteoarthritis	Grde2 Moderate	Not Related,
MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2034-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2035-Q	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2035-Q	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2036-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Neutropenia	Grade 1 Mild	Possibly -/Related
MA-22-2036-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2036-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2036-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Neutropenia	Grade 1 Mild	Unlikely Related
MA-22-2036-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Abdominal pain	Grade 1 Mild	Not Related,
MA-22-2037-S	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2038-T	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2038-T	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-2038-T	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2038-T	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grde2 Moderate	Not Related,
MA-22-2039-U	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2039-U	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Probably Related,
MA-22-2039-U	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related

MA-22-2039-U	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2039-U	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2039-U	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2040-V	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2040-V	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2040-V	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2041-W	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grde2 Moderate	Not Related,
MA-22-2041-W	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grde2 Moderate	Not Related,
MA-22-2041-W	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2041-W	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2044-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grde2 Moderate	Not Related,
MA-22-2044-B	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Paronychia	Grade 1 Mild	Not Related,
MA-22-2045-C	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2045-C	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Neutropenia	Grade 1 Mild	Not Related,
MA-22-2045-C	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2046-D	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grde2 Moderate	Probably Related,
MA-22-2046-D	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-2046-D	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grade 1 Mild	Unlikely Related
MA-22-2046-D	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2047-E	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2047-E	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Abdominal pain	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,

MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2048-F	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Abscess	Grade 1 Mild	Not Related,
MA-22-2049-G	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Diarrhoea	Grade 1 Mild	Not Related,
MA-22-2050-H	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Elevated ALT	Grade 1 Mild	Probably Related,
MA-22-2050-H	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2050-H	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Osteoarthritis	Grade 2 Moderate	Not Related,
MA-22-2051-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2051-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2051-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2051-J	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2052-A	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,

MA-22-2053-D	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2054-B	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2055-C	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2055-C	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2056-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2056-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2056-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2056-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2056-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Epigastralgia	Grade 1 Mild	Not Related,
MA-22-2058-P	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2059-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2059-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Epigastralgia	Grade 1 Mild	Not Related,
MA-22-2059-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2059-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2059-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Definitively/Related
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Chest Pain	Grde2 Moderate	Unlikely Related

MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Unlikely Related
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Wound	Grade 1 Mild	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Inguinal hernia	Grade3 Severe	Not Related,
MA-22-2060-V	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2061-P	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2061-P	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Leukopenia	Grde2 Moderate	Possibly -/Related
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grde2 Moderate	Not Related,
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Neutropenia	Grade 1 Mild	Possibly -/Related
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2062-Q	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2063-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2064-A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2064-A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2064-A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Possibly -/Related

MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Possibly -/Related
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2065-R	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2066-M	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Possibly -/Related
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2067-S	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Anorexia	Grade 1 Mild	Not Related,
MA-22-2068-Y	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2069-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2069-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2069-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Orchite	Grade 1 Mild	Not Related,
MA-22-2069-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2069-E	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2070-G	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2070-G	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2070-G	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,

MA-22-2070-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2070-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Probably Related,
MA-22-2070-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2070-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2071-T	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Epigastralgia	Grade 1 Mild	Not Related,
MA-22-2071-T	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2072-F	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2072-F	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2072-F	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2073-P	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Wound	Grade 1 Mild	Not Related,
MA-22-2074-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2074-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2074-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2074-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2075-K	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2075-K	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2076-C	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2076-C	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Neutropenia	Grade 1 Mild	Unlikely Related
MA-22-2076-C	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2076-C	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2077-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related

MA-22-2077-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2077-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2077-K	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2078-A	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2078-A	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2079-N	Comparator Vaccine (Rabies) and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2079-N	Comparator Vaccine (Rabies) and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2080-M	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2080-M	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2080-M	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2081-A	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2081-A	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Leukopenia	Grade 1 Mild	Not Related,
MA-22-2081-A	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Wound	Grade 1 Mild	Not Related,
MA-22-2082-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2082-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2082-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2082-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Leukopenia	Grade 1 Mild	Possibly -/Related
MA-22-2082-R	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,

MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grde2 Moderate	Not Related,
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2083-H	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2084-Z	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2084-Z	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2085-T	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Probably Related,
MA-22-2085-T	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Hemoglobin increased	Grade 1 Mild	Not Related,
MA-22-2087-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2087-G	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2088-S	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Anaemia	Grade 1 Mild	Unlikely Related
MA-22-2089-E	Comparator Vaccine (Rabies) and normal saline	Conjunctival hyperaemia	Grade 1 Mild	Not Related,
MA-22-2089-E	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2090-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2090-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2090-D	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2091-X	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2091-X	Comparator Vaccine (Rabies) and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2092-X	Comparator Vaccine (Rabies) and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,

MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Headaches	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2095-B	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Headaches	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2096-Q	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2097-T	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Wound	Grade 1 Mild	Not Related,
MA-22-2098-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2098-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-2098-U	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-2099-Z	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2099-Z	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Rhinitis	Grade 1 Mild	Not Related,
MA-22-2099-Z	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	Urticaria	Grade 1 Mild	Not Related,

MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3003-B	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Neutropenia	Grade 1 Mild	Probably Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Leukopenia	Grade 1 Mild	Probably Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grde2 Moderate	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grde2 Moderate	Definitively/Related
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Leukopenia	Grade 1 Mild	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Neutropenia	Grade 1 Mild	Not Related,
MA-22-3014-D	40µg Pfs230D1-EPA+50µg Matrix-M	Headaches	Grade 1 Mild	Not Related,
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Leukopenia	Grade 1 Mild	Not Related,
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Neutropenia	Grade 1 Mild	Not Related,
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Headaches	Grade 1 Mild	Possibly -/Related
MA-22-3088-C	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	Headaches	Grade 1 Mild	Not Related,
MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	Neutropenia	Grade 1 Mild	Not Related,
MA-22-3097-E	40µg Pfs230D1-EPA+50µg Matrix-M	Acute Malaria	Grade 1 Mild	Not Related,
MA-22-3102-B	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3102-B	40µg Pfs230D1-EPA+50µg Matrix-M	Injection site pain	Grade 1 Mild	Definitively/Related
MA-22-3102-B	40µg Pfs230D1-EPA+50µg Matrix-M	Rhinitis	Grade 1 Mild	Not Related,

Table 12: List of Adverse Events by Group and Subject-Vaccination

Study ID	Arm	Products Received	Date of First Dose of Vaccine	Date of Latest Dose of Vaccine Prior to AE	Days from Latest Dose Vaccine to Onset of AE	AE Description	Onset Date	End Date
MA-22-1001-A	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	40	Headaches	18-Nov-22	21-Nov-22
MA-22-1001-A	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	310	Sinobronchitis	15-Aug-23	22-Aug-23
MA-22-1002-B	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	21	Acute Malaria	30-Oct-22	1-Nov-22
MA-22-1002-B	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	46	Acute Malaria	24-Nov-22	26-Nov-22
MA-22-1003-C	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	-49	Back pain	21-Aug-22	23-Aug-22
MA-22-1003-C	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	1	Injection site pain	10-Oct-22	11-Oct-22
MA-22-1003-C	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	14	Leukopenia	23-Oct-22	6-Nov-22
MA-22-1003-C	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	-51	Rhinitis	19-Aug-22	21-Aug-22
MA-22-1004-D	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	1	Injection site pain	10-Oct-22	11-Oct-22
MA-22-1004-D	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	43	Rhinitis	21-Nov-22	23-Nov-22
MA-22-1004-D	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	336	Rhinitis	10-Sep-23	16-Sep-23
MA-22-1004-D	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	336	Acute Malaria	10-Sep-23	16-Sep-23
MA-22-1004-D	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	340	Injection site movement impairment	14-Sep-23	14-Oct-23
MA-22-1005-E	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	27	Acute Malaria	5-Nov-22	6-Nov-22

MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	12	Acute Malaria	21-Oct-22	23-Oct-22
MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	14	Neutropenia	23-Oct-22	6-Nov-22
MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	72	Rhinitis	20-Dec-22	3-Jan-23
MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	254	Headaches	20-Jun-23	22-Jun-23
MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	277	Otitis externa	13-Jul-23	15-Jul-23
MA-22-1006-G	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	316	Acute Malaria	21-Aug-23	23-Aug-23
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	-28	Neutropenia	11-Sep-22	14-Sep-22
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	-27	Injection site pain	12-Sep-22	13-Sep-22
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	1	Injection site pain	10-Oct-22	11-Oct-22
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	3	Leukopenia	12-Oct-22	23-Nov-22
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	3	Neutropenia	12-Oct-22	23-Nov-22
MA-22-1007-H	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	340	Headaches	14-Sep-23	18-Sep-23
MA-22-1008-J	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	-27	Injection site pain	12-Sep-22	13-Sep-22
MA-22-1008-J	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	3	Neutropenia	12-Oct-22	23-Oct-22
MA-22-1008-J	1B	30µg R0.6C-A1OH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	14-Aug-22	9-Oct-22	43	Rhinitis	21-Nov-22	21-Nov-22
MA-22-1009-K	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	0	Injection site pain	9-Oct-22	11-Oct-22
MA-22-1009-K	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	3	Neutropenia	12-Oct-22	23-Nov-22

MA-22-1009-K	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	57	Acute Malaria	5-Dec-22	7-Dec-22
MA-22-1009-K	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	281	Rhinitis	17-Jul-23	19-Jul-23
MA-22-1010-M	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	-50	Rhinitis	20-Aug-22	22-Aug-22
MA-22-1010-M	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	-2	Rhinitis	7-Oct-22	9-Oct-22
MA-22-1010-M	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	-2	Acute Malaria	7-Oct-22	9-Oct-22
MA-22-1010-M	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	1	Injection site pruritus	10-Oct-22	11-Oct-22
MA-22-1010-M	1C	Comparator Vaccine (Rabies) and normal saline	14-Aug-22	9-Oct-22	41	Rhinitis	19-Nov-22	20-Nov-22
MA-22-2002-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	20-Oct-22
MA-22-2002-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	2	Injection site pain	16-Nov-22	21-Nov-22
MA-22-2002-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	300	Vomiting	10-Sep-23	11-Sep-23
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-56	Injection site pain	19-Sep-22	19-Sep-22
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	6	Acute Malaria	20-Nov-22	22-Nov-22
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	14	Leukocytosis	28-Nov-22	12-Dec-22
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	31	Headaches	15-Dec-22	20-Dec-22
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	60	Headaches	13-Jan-23	14-Jan-23
MA-22-2003-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	300	Acute Malaria	10-Sep-23	12-Sep-23
MA-22-2004-K	2D	100µg R0.6C-A1OH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-55	Injection site pain	20-Sep-22	21-Sep-22
MA-22-2004-K	2D	100µg R0.6C-A1OH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	20-Oct-22

MA-22-2004-K	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	59	Wound	12-Jan-23	17-Jan-23
MA-22-2005-C	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-55	Injection site pain	20-Sep-22	21-Sep-22
MA-22-2005-C	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	24-Oct-22
MA-22-2006-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-55	Injection site pain	20-Sep-22	21-Sep-22
MA-22-2006-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-1	Acute Malaria	13-Nov-22	16-Nov-22
MA-22-2006-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	0	Thrombocytopenia	14-Nov-22	17-Nov-22
MA-22-2007-P	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-42	Rhinitis	3-Oct-22	6-Oct-22
MA-22-2007-P	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	220	Rhinitis	22-Jun-23	24-Jun-23
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-49	Headaches	26-Sep-22	28-Sep-22
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-37	Acute Malaria	8-Oct-22	10-Oct-22
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-37	Rhinitis	8-Oct-22	10-Oct-22
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	0	Injection site pain	14-Nov-22	17-Nov-22
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	3	Acute Malaria	17-Nov-22	19-Nov-22
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	299	Nausea	9-Sep-23	10-Sep-23
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	299	Abdominal pain	9-Sep-23	10-Sep-23
MA-22-2008-A	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	322	Headaches	2-Oct-23	5-Oct-23
MA-22-2009-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	20-Oct-22
MA-22-2009-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-11	Acute Malaria	3-Nov-22	5-Nov-22

MA-22-2010-M	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-28	Injection site pain	17-Oct-22	19-Oct-22
MA-22-2010-M	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-21	Acute Malaria	24-Oct-22	26-Oct-22
MA-22-2011-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Elevated creatinine	20-Oct-22	14-Nov-22
MA-22-2011-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	0	Leukopenia	14-Nov-22	18-Nov-22
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-25	Neutropenia	20-Oct-22	31-Oct-22
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-25	Leukopenia	20-Oct-22	31-Oct-22
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-20	Acute Malaria	25-Oct-22	27-Oct-22
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-14	Elevated ALT	31-Oct-22	14-Nov-22
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	272	Headaches	13-Aug-23	14-Aug-23
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	272	Dizziness	13-Aug-23	14-Aug-23
MA-22-2012-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	304	Headaches	14-Sep-23	18-Sep-23
MA-22-2013-H	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-30	Genital infection	15-Oct-22	27-Oct-22
MA-22-2013-H	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-28	Elevated creatinine	17-Oct-22	31-Oct-22
MA-22-2013-H	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	125	Thermal burn	19-Mar-23	2-Apr-23
MA-22-2013-H	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	322	Chest Pain	2-Oct-23	5-Oct-23
MA-22-2014-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-56	Injection site pain	19-Sep-22	21-Sep-22
MA-22-2014-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	0	Tonsillitis	14-Nov-22	15-Nov-22
MA-22-2014-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	9	Rhinitis	23-Nov-22	25-Nov-22

MA-22-2014-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	218	Headaches	20-Jun-23	22-Jun-23
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-55	Injection site pain	20-Sep-22	21-Sep-22
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-28	Aches	17-Oct-22	20-Oct-22
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Injection site pain	15-Nov-22	17-Nov-22
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	9	Headaches	23-Nov-22	24-Nov-22
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	14	Neutropenia	28-Nov-22	12-Dec-22
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	53	Headaches	6-Jan-23	9-Jan-23
MA-22-2015-D	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	280	Rhinitis	21-Aug-23	27-Aug-23
MA-22-2016-T	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	23	Rhinitis	7-Dec-22	8-Dec-22
MA-22-2017-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	105	Rhinitis	27-Feb-23	2-Mar-23
MA-22-2017-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	302	Headaches	12-Sep-23	18-Sep-23
MA-22-2017-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	333	Headaches	13-Oct-23	14-Oct-23
MA-22-2018-V	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-24	Injection site pain	21-Oct-22	24-Oct-22
MA-22-2018-V	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	2	Injection site pain	16-Nov-22	16-Nov-22
MA-22-2018-V	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	280	Sinobronchitis	21-Aug-23	28-Aug-23
MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	19-Oct-22
MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Injection site pain	15-Nov-22	17-Nov-22
MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	3	Leukopenia	17-Nov-22	28-Nov-22

MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	29	Leukopenia	13-Dec-22	7-Feb-23
MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	135	Abscess	29-Mar-23	5-Apr-23
MA-22-2019-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	330	Rhinitis	10-Oct-23	12-Oct-23
MA-22-2020-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-49	Injection site pruritus	26-Sep-22	27-Sep-22
MA-22-2020-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	20-Oct-22
MA-22-2020-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Leukopenia	20-Oct-22	17-Nov-22
MA-22-2020-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	0	Injection site pain	14-Nov-22	15-Nov-22
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-35	Leukopenia	10-Oct-22	17-Oct-22
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-1	Acute Malaria	13-Nov-22	15-Nov-22
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	22	Sinobronchitis	6-Dec-22	12-Dec-22
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	28	Leukopenia	12-Dec-22	9-Jan-23
MA-22-2021-Z	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	315	Acute Malaria	25-Sep-23	27-Sep-23
MA-22-2022-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	237	Rhinitis	9-Jul-23	11-Jul-23
MA-22-2022-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	237	Acute Malaria	9-Jul-23	11-Jul-23
MA-22-2023-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	20-Oct-22
MA-22-2023-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-3	Headaches	11-Nov-22	14-Nov-22
MA-22-2024-B	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	109	Rhinitis	3-Mar-23	13-Mar-23
MA-22-2024-B	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	109	Acute Malaria	3-Mar-23	6-Mar-23
MA-22-2025-C	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Neutropenia	20-Oct-22	31-Oct-22

MA-22-2025-C	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	320	Injection site movement impairment	30-Sep-23	17-Nov-23
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-41	Neutropenia	4-Oct-22	11-Oct-22
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	21-Oct-22
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-20	Headaches	25-Oct-22	26-Oct-22
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-13	Leukopenia	1-Nov-22	15-Nov-22
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	29	Neutropenia	13-Dec-22	7-Feb-23
MA-22-2026-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	331	Acute Malaria	11-Oct-23	13-Oct-23
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	19-Oct-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-5	Rhinitis	9-Nov-22	15-Nov-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-5	Acute Malaria	9-Nov-22	15-Nov-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	10	Rhinitis	24-Nov-22	29-Nov-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-218	Neutropenia	10-Apr-22	21-Oct-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-41	Leukopenia	4-Oct-22	21-Oct-22
MA-22-2027-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	280	Rhinitis	21-Aug-23	26-Aug-23
MA-22-2028-G	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	116	Rhinitis	10-Mar-23	12-Mar-23
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-16	Acute Malaria	29-Oct-22	31-Oct-22
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Headaches	18-Nov-22	21-Nov-22
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	23	Headaches	7-Dec-22	8-Dec-22
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	64	Aches	17-Jan-23	17-Jan-23

MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	105	Rhinitis	27-Feb-23	28-Feb-23
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	250	Headaches	22-Jul-23	26-Jul-23
MA-22-2029-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	262	Headaches	3-Aug-23	10-Aug-23
MA-22-2030-J	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-4	Rhinitis	10-Nov-22	16-Nov-22
MA-22-2030-J	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-3	Acute Malaria	11-Nov-22	13-Nov-22
MA-22-2031-K	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Rhinitis	15-Nov-22	16-Nov-22
MA-22-2031-K	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Acute Malaria	15-Nov-22	16-Nov-22
MA-22-2031-K	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	322	Acute Malaria	2-Oct-23	4-Oct-23
MA-22-2032-M	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-20	Sinobronchitis	25-Oct-22	27-Oct-22
MA-22-2032-M	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	328	Acute Malaria	8-Oct-23	10-Oct-23
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	107	Injection site movement impairment	1-Mar-23	28-Mar-23
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	318	Rhinitis	28-Sep-23	5-Oct-23
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-52	Leukopenia	23-Sep-22	4-Oct-22
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	21-Oct-22
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-6	Sinobronchitis	8-Nov-22	15-Nov-22
MA-22-2033-N	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	0	Headaches	14-Nov-22	16-Nov-22
MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-13	Injection site pain	1-Nov-22	2-Nov-22
MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-13	Osteoarthritis	1-Nov-22	15-Dec-22
MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Headaches	15-Nov-22	20-Nov-22

MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	280	Rhinitis	21-Aug-23	27-Aug-23
MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	332	Rhinitis	12-Oct-23	14-Oct-23
MA-22-2034-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	332	Acute Malaria	12-Oct-23	14-Oct-23
MA-22-2035-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-15	Rhinitis	30-Oct-22	1-Nov-22
MA-22-2035-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-15	Acute Malaria	30-Oct-22	1-Nov-22
MA-22-2036-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-41	Neutropenia	4-Oct-22	10-Oct-22
MA-22-2036-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-37	Acute Malaria	8-Oct-22	10-Oct-22
MA-22-2036-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	21-Oct-22
MA-22-2036-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-13	Neutropenia	1-Nov-22	15-Nov-22
MA-22-2036-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	50	Abdominal pain	3-Jan-23	6-Jan-23
MA-22-2037-S	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	2	Injection site pain	16-Nov-22	17-Nov-22
MA-22-2038-T	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	20-Oct-22
MA-22-2038-T	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Leukopenia	18-Nov-22	29-Nov-22
MA-22-2038-T	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	20	Acute Malaria	4-Dec-22	6-Dec-22
MA-22-2038-T	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	116	Acute Malaria	10-Mar-23	12-Mar-23
MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-54	Injection site pain	21-Sep-22	22-Sep-22
MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-52	Headaches	23-Sep-22	24-Sep-22

MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	25-Oct-22
MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-16	Rhinitis	29-Oct-22	6-Nov-22
MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	2	Injection site pain	16-Nov-22	21-Nov-22
MA-22-2039-U	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	90	Headaches	12-Feb-23	13-Feb-23
MA-22-2040-V	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-52	Rhinitis	23-Sep-22	25-Sep-22
MA-22-2040-V	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Acute Malaria	15-Nov-22	17-Nov-22
MA-22-2040-V	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	302	Acute Malaria	12-Sep-23	15-Sep-23
MA-22-2041-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	14	Rhinitis	28-Nov-22	30-Nov-22
MA-22-2041-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	14	Acute Malaria	28-Nov-22	30-Nov-22
MA-22-2041-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	293	Rhinitis	3-Sep-23	6-Sep-23
MA-22-2041-W	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	293	Acute Malaria	3-Sep-23	6-Sep-23
MA-22-2044-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-32	Acute Malaria	13-Oct-22	15-Oct-22
MA-22-2044-B	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-24	Paronychia	21-Oct-22	25-Oct-22
MA-22-2045-C	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-54	Injection site pain	21-Sep-22	22-Sep-22
MA-22-2045-C	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	29	Neutropenia	13-Dec-22	6-Feb-23
MA-22-2045-C	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	60	Acute Malaria	13-Jan-23	15-Jan-23
MA-22-2046-D	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-52	Neutropenia	23-Sep-22	10-Oct-22
MA-22-2046-D	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-52	Leukopenia	23-Sep-22	10-Oct-22

MA-22-2046-D	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-13	Leukopenia	1-Nov-22	13-Dec-22
MA-22-2046-D	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	324	Rhinitis	4-Oct-23	6-Oct-23
MA-22-2047-E	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	20-Oct-22
MA-22-2047-E	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	37	Abdominal pain	21-Dec-22	25-Dec-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-21	Rhinitis	24-Oct-22	3-Nov-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	1	Leukopenia	15-Nov-22	18-Nov-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Rhinitis	18-Nov-22	21-Nov-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Acute Malaria	18-Nov-22	20-Nov-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	17	Rhinitis	1-Dec-22	3-Dec-22
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	47	Rhinitis	31-Dec-22	6-Jan-23
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	47	Acute Malaria	31-Dec-22	2-Jan-23
MA-22-2048-F	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	338	Acute Malaria	18-Oct-23	20-Oct-23
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-34	Headaches	11-Oct-22	18-Oct-22
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	21-Oct-22
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-8	Acute Malaria	6-Nov-22	6-Nov-22
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	34	Acute Malaria	18-Dec-22	21-Dec-22
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	195	Abscess	28-May-23	22-Jun-23
MA-22-2049-G	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	322	Diarrhoea	2-Oct-23	4-Oct-23

MA-22-2050-H	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-52	Elevated ALT	23-Sep-22	4-Oct-22
MA-22-2050-H	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-27	Injection site pain	18-Oct-22	19-Oct-22
MA-22-2050-H	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	43	Osteoarthritis	27-Dec-22	17-Feb-23
MA-22-2051-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	23-Sep-22
MA-22-2051-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-36	Rhinitis	9-Oct-22	11-Oct-22
MA-22-2051-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-36	Acute Malaria	9-Oct-22	11-Oct-22
MA-22-2051-J	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	22-Oct-22
MA-22-2052-A	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-16	Acute Malaria	29-Oct-22	31-Oct-22
MA-22-2053-D	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-54	Injection site pain	21-Sep-22	21-Sep-22
MA-22-2054-B	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-7	Acute Malaria	7-Nov-22	16-Nov-22
MA-22-2055-C	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	330	Rhinitis	10-Oct-23	12-Oct-23
MA-22-2055-C	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	330	Acute Malaria	10-Oct-23	12-Oct-23
MA-22-2056-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	22-Oct-22
MA-22-2056-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	3	Injection site pain	17-Nov-22	19-Nov-22
MA-22-2056-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	33	Rhinitis	17-Dec-22	27-Dec-22
MA-22-2056-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	98	Headaches	20-Feb-23	25-Feb-23
MA-22-2056-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	267	Epigastralgia	8-Aug-23	17-Aug-23
MA-22-2058-P	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-26	Rhinitis	19-Oct-22	21-Oct-22

MA-22-2059-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Leukopenia	19-Oct-22	2-Nov-22
MA-22-2059-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Epigastralgia	19-Oct-22	22-Oct-22
MA-22-2059-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-8	Rhinitis	6-Nov-22	7-Nov-22
MA-22-2059-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-8	Acute Malaria	6-Nov-22	6-Nov-22
MA-22-2059-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	334	Acute Malaria	14-Oct-23	17-Oct-23
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	24-Sep-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Headaches	22-Sep-22	23-Sep-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-29	Injection site pain	16-Oct-22	19-Oct-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Rhinitis	19-Oct-22	20-Oct-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	23-Oct-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-19	Chest Pain	26-Oct-22	27-Oct-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-19	Headaches	26-Oct-22	27-Oct-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	2	Acute Malaria	16-Nov-22	19-Nov-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	16	Rhinitis	30-Nov-22	1-Dec-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	45	Acute Malaria	29-Dec-22	31-Dec-22
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	156	Headaches	19-Apr-23	28-Apr-23
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	165	Wound	28-Apr-23	28-Apr-23
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	210	Inguinal hernia	12-Jun-23	26-Jun-23
MA-22-2060-V	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	321	Acute Malaria	1-Oct-23	4-Oct-23

MA-22-2061-P	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	28-Sep-22
MA-22-2061-P	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	22-Oct-22
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-26	Rhinitis	19-Oct-22	22-Oct-22
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-23	Leukopenia	22-Oct-22	16-Nov-22
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-23	Neutropenia	22-Oct-22	2-Nov-22
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	16	Neutropenia	30-Nov-22	14-Dec-22
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	74	Acute Malaria	27-Jan-23	30-Jan-23
MA-22-2062-Q	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	336	Acute Malaria	16-Oct-23	18-Oct-23
MA-22-2063-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	17	Leukopenia	1-Dec-22	14-Dec-22
MA-22-2064-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	20-Oct-22
MA-22-2064-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	6	Rhinitis	20-Nov-22	21-Nov-22
MA-22-2064-A	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	30	Rhinitis	14-Dec-22	24-Dec-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-44	Rhinitis	1-Oct-22	5-Oct-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-44	Acute Malaria	1-Oct-22	3-Oct-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-40	Neutropenia	5-Oct-22	19-Oct-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-40	Leukopenia	5-Oct-22	2-Nov-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	2	Leukopenia	16-Nov-22	14-Dec-22
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	46	Headaches	30-Dec-22	3-Jan-23
MA-22-2065-R	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	199	Headaches	1-Jun-23	1-Jun-23

MA-22-2066-M	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-16	Acute Malaria	29-Oct-22	1-Nov-22
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	26-Oct-22
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-23	Leukopenia	22-Oct-22	2-Nov-22
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-23	Neutropenia	22-Oct-22	2-Nov-22
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Rhinitis	18-Nov-22	20-Nov-22
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	265	Rhinitis	6-Aug-23	10-Aug-23
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	287	Headaches	28-Aug-23	29-Aug-23
MA-22-2067-S	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	287	Anorexia	28-Aug-23	29-Aug-23
MA-22-2068-Y	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	70	Headaches	23-Jan-23	27-Jan-23
MA-22-2069-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	23-Sep-22
MA-22-2069-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	22-Oct-22
MA-22-2069-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	193	Orchite	26-May-23	3-Jun-23
MA-22-2069-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	310	Headaches	20-Sep-23	27-Sep-23
MA-22-2069-E	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	321	Acute Malaria	1-Oct-23	4-Oct-23
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	23-Sep-22
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-45	Rhinitis	30-Sep-22	2-Oct-22
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-45	Acute Malaria	30-Sep-22	2-Oct-22
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	22-Oct-22

MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Headaches	20-Oct-22	22-Oct-22
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-6	Rhinitis	8-Nov-22	13-Nov-22
MA-22-2070-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	338	Acute Malaria	18-Oct-23	20-Oct-23
MA-22-2071-T	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-23	Epigastralgia	22-Oct-22	21-Oct-22
MA-22-2071-T	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	265	Rhinitis	6-Aug-23	12-Aug-23
MA-22-2072-F	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-46	Rhinitis	29-Sep-22	1-Oct-22
MA-22-2072-F	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-46	Acute Malaria	29-Sep-22	1-Oct-22
MA-22-2072-F	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	3	Injection site pain	17-Nov-22	19-Nov-22
MA-22-2073-P	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-5	Wound	9-Nov-22	16-Nov-22
MA-22-2074-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-26	Injection site pain	19-Oct-22	26-Oct-22
MA-22-2074-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	13	Acute Malaria	27-Nov-22	29-Nov-22
MA-22-2074-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	49	Headaches	2-Jan-23	6-Jan-23
MA-22-2074-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	338	Acute Malaria	18-Oct-23	20-Oct-23
MA-22-2075-K	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	3	Injection site pain	17-Nov-22	19-Nov-22
MA-22-2075-K	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	9	Rhinitis	23-Nov-22	25-Nov-22
MA-22-2076-C	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-24	Injection site pain	21-Oct-22	22-Oct-22
MA-22-2076-C	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-22	Neutropenia	23-Oct-22	3-Nov-22
MA-22-2076-C	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Injection site pain	18-Nov-22	21-Nov-22

MA-22-2076-C	2B	100µg ProC6C-AlOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	331	Headaches	11-Oct-23	13-Oct-23
MA-22-2077-K	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-52	Injection site pain	23-Sep-22	24-Sep-22
MA-22-2077-K	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Injection site pain	18-Nov-22	20-Nov-22
MA-22-2077-K	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	10	Rhinitis	24-Nov-22	26-Nov-22
MA-22-2077-K	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	10	Acute Malaria	24-Nov-22	26-Nov-22
MA-22-2078-A	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-50	Injection site pain	25-Sep-22	28-Sep-22
MA-22-2078-A	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Injection site pain	18-Nov-22	21-Nov-22
MA-22-2079-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-16	Headaches	29-Oct-22	30-Oct-22
MA-22-2079-N	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	308	Rhinitis	18-Sep-23	20-Sep-23
MA-22-2080-M	2A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	24-Sep-22
MA-22-2080-M	2A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	22-Oct-22
MA-22-2080-M	2A	100µg R0.6C-AlOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	304	Headaches	14-Sep-23	18-Sep-23
MA-22-2081-A	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-33	Acute Malaria	12-Oct-22	14-Oct-22
MA-22-2081-A	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	17	Leukopenia	1-Dec-22	6-Feb-23
MA-22-2081-A	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	287	Wound	28-Aug-23	1-Sep-23
MA-22-2082-R	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-24	Rhinitis	21-Oct-22	23-Oct-22
MA-22-2082-R	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-24	Injection site pain	21-Oct-22	23-Oct-22
MA-22-2082-R	2D	100µg R0.6C-AlOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	2	Acute Malaria	16-Nov-22	19-Nov-22

MA-22-2082-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	3	Leukopenia	17-Nov-22	20-Nov-22
MA-22-2082-R	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	31	Headaches	15-Dec-22	20-Dec-22
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-50	Injection site pain	25-Sep-22	27-Sep-22
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-7	Rhinitis	7-Nov-22	14-Nov-22
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-7	Acute Malaria	7-Nov-22	10-Nov-22
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	104	Acute Malaria	26-Feb-23	27-Feb-23
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	210	Rhinitis	12-Jun-23	15-Jun-23
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	334	Rhinitis	14-Oct-23	16-Oct-23
MA-22-2083-H	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	334	Acute Malaria	14-Oct-23	16-Oct-23
MA-22-2084-Z	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	24-Sep-22
MA-22-2084-Z	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-23	Headaches	22-Oct-22	23-Oct-22
MA-22-2085-T	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-46	Headaches	29-Sep-22	30-Sep-22
MA-22-2085-T	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	17	Hemoglobin increased	1-Dec-22	15-Dec-22
MA-22-2087-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-22	Injection site pain	23-Oct-22	27-Oct-22
MA-22-2087-G	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	3	Injection site pain	17-Nov-22	20-Nov-22
MA-22-2088-S	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	3	Anaemia	17-Nov-22	20-Nov-22
MA-22-2089-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	223	Conjunctival hyperaemia	25-Jun-23	29-Jun-23
MA-22-2089-E	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	326	Acute Malaria	6-Oct-23	8-Oct-23

MA-22-2090-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	23-Sep-22
MA-22-2090-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	30	Rhinitis	14-Dec-22	24-Dec-22
MA-22-2090-D	2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	30	Acute Malaria	14-Dec-22	17-Dec-22
MA-22-2091-X	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-53	Injection site pain	22-Sep-22	22-Sep-22
MA-22-2091-X	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-25	Injection site pain	20-Oct-22	21-Oct-22
MA-22-2092-X	2E	Comparator Vaccine (Rabies) and normal saline	19-Sep-22	14-Nov-22	-13	Acute Malaria	1-Nov-22	3-Nov-22
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-54	Headaches	21-Sep-22	23-Sep-22
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	-35	Acute Malaria	10-Oct-22	12-Oct-22
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	49	Rhinitis	2-Jan-23	6-Jan-23
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	49	Acute Malaria	2-Jan-23	4-Jan-23
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	196	Headaches	29-May-23	30-May-23
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	251	Rhinitis	23-Jul-23	1-Aug-23
MA-22-2095-B	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	302	Acute Malaria	12-Sep-23	15-Sep-23
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-52	Injection site pain	23-Sep-22	25-Sep-22
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-32	Acute Malaria	13-Oct-22	15-Oct-22
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	19	Rhinitis	3-Dec-22	5-Dec-22
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	35	Headaches	19-Dec-22	20-Dec-22
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	43	Acute Malaria	27-Dec-22	29-Dec-22

MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	118	Rhinitis	12-Mar-23	19-Mar-23
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	238	Rhinitis	10-Jul-23	12-Jul-23
MA-22-2096-Q	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	255	Rhinitis	27-Jul-23	29-Jul-23
MA-22-2097-T	2D	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	19-Sep-22	14-Nov-22	94	Wound	16-Feb-23	30-Mar-23
MA-22-2098-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-22	Rhinitis	23-Oct-22	27-Oct-22
MA-22-2098-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-22	Acute Malaria	23-Oct-22	26-Oct-22
MA-22-2098-U	2B	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Injection site pain	18-Nov-22	20-Nov-22
MA-22-2099-Z	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-46	Rhinitis	29-Sep-22	2-Oct-22
MA-22-2099-Z	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	-25	Rhinitis	20-Oct-22	21-Oct-22
MA-22-2099-Z	2A	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	19-Sep-22	14-Nov-22	4	Injection site pain	18-Nov-22	20-Nov-22
MA-22-3003-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	19-Sep-22	14-Nov-22	-39	Acute Malaria	6-Oct-22	9-Oct-22
MA-22-3003-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	19-Sep-22	14-Nov-22	-13	Injection site pain	1-Nov-22	2-Nov-22
MA-22-3003-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-112	Urticaria	28-Nov-22	1-Dec-22
MA-22-3003-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	1	Injection site pain	21-Mar-23	22-Mar-23
MA-22-3003-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	257	Acute Malaria	2-Dec-23	4-Dec-23
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-165	Neutropenia	6-Oct-22	3-Nov-22
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-165	Leukopenia	6-Oct-22	3-Nov-22
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-159	Acute Malaria	12-Oct-22	14-Oct-22

MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-139	Injection site pain	1-Nov-22	2-Nov-22
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-121	Rhinitis	19-Nov-22	21-Nov-22
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-103	Rhinitis	7-Dec-22	13-Dec-22
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	1	Injection site pain	21-Mar-23	22-Mar-23
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	0	Leukopenia	20-Mar-23	17-Apr-23
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	0	Neutropenia	20-Mar-23	17-Apr-23
MA-22-3014-D	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	189	Headaches	25-Sep-23	26-Sep-23
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-140	Injection site pain	31-Oct-22	1-Nov-22
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-137	Acute Malaria	3-Nov-22	5-Nov-22
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-137	Leukopenia	3-Nov-22	14-Nov-22
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-137	Neutropenia	3-Nov-22	14-Nov-22
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	1	Headaches	21-Mar-23	22-Mar-23
MA-22-3088-C	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	155	Acute Malaria	22-Aug-23	24-Aug-23
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-142	Headaches	29-Oct-22	31-Oct-22
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-139	Injection site pain	1-Nov-22	2-Nov-22
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	1	Injection site pain	21-Mar-23	24-Mar-23
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	14	Neutropenia	3-Apr-23	17-Apr-23
MA-22-3097-E	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	171	Acute Malaria	7-Sep-23	9-Sep-23
MA-22-3102-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	-139	Injection site pain	1-Nov-22	4-Nov-22

MA-22-3102-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	1	Injection site pain	21-Mar-23	22-Mar-23
MA-22-3102-B	Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	3-Oct-22	20-Mar-23	73	Rhinitis	1-Jun-23	2-Jun-23

Table 13: Frequency of Adverse Events by group, products received and by severity (Group1/group2)

Arm/Severity	Study Product	Grade 1 Mild	Grde2 Moderate	Grade3 Severe	Overall
		N = 3701	N = 251	N = 31	N = 3981
1B	30µg R0.6C-ALOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	15 (79%)	4 (21%)	0 (0%)	19 (100%)
1C	Comparator Vaccine (Rabies) and normal saline	17 (89%)	1 (5.3%)	1 (5.3%)	19 (100%)
2A	100µg R0.6C-ALOH+50µg Matrix-M and normal saline	59 (95%)	3 (4.8%)	0 (0%)	62 (100%)
2B	100µg ProC6C-ALOH+50µg Matrix-M and normal saline	60 (94%)	4 (6.3%)	0 (0%)	64 (100%)
2C	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	82 (93%)	5 (5.7%)	1 (1.1%)	88 (100%)
2D	100µg R0.6C-ALOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	61 (100%)	0 (0%)	0 (0%)	61 (100%)
2E	Comparator Vaccine (Rabies) and normal saline	49 (88%)	6 (11%)	1 (1.8%)	56 (100%)
Arm3	40µg Pfs230D1-EPA+50µg Matrix-M	27 (93%)	2 (6.9%)	0 (0%)	29 (100%)
¹ n (%)					

Table 14: Frequency of Grade-2 or higher laboratory Adverse Events by group and causality (Group 1/Group 2)

Body System MedDRA Term	MedDRA Preferred Term	Study product	Group 1/Group 2					
			Not Related	Related	Not Related	Related	Not Related	Related
			Vac#1		Vac#2		Vac#3	
NEUTROPENIA	Blood and lymphatic system disorders	[1B]	0 (0 %)	0 (0 %)	1 (20%)	0 (0 %)	1 (20%)	1 (20%)
		[2E]	0 (0 %)	1 (5%)	1 (5%)	1 (5%)	0 (0 %)	0 (0 %)
LEUKOCYTOSIS	Blood and lymphatic system disorders	[2E]	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)	1 (5%)	0 (0 %)
THROMBOPENIA	Blood and lymphatic system disorders	[2A]	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)	0 (0 %)	1 (5%)
LEUCOPENIA	Blood and lymphatic system disorders	[2B]	0 (0 %)	0 (0 %)	0 (0 %)	1 (5%)	0 (0 %)	0 (0 %)
		[2E]	0 (0 %)	0 (0 %)	0 (0 %)	1 (5%)	0 (0 %)	0 (0 %)

Table 15: Frequency of Grade 3 Adverse Events by Group and causality (Group1/group2)

Body System MedDRA Term	MedDRA Preferred Term	Study product	Group 1/Group 2					
			Not Related	Related	Not Related	Related	Not Related	Related
			Vac#1		Vac#2		Vac#3	
Acute malaria	Malaria,Infections and infestations	[1C]	1 (20%)	0 (0 %)	0 (0 %)	0 (0) 0 %	0 (0 %)	0 (0) 0 %
Elevated ALT	Blood creatinine increased,Investigations	[2E]	0 (0 %)	0 (0 %)	1 (5%)	0 (0) 0 %	0 (0) 0 %	0 (0) 0 %
Inguinal hernia	Inguinal hernia,Gastrointestinal disorders	[2C]	0 (0 %)	0 (0 %)	0 (0 %)	0 (0) 0 %	1 (5%)	0 (0) 0 %

Table 16: Frequency of adverse events by Group and products received (Group1/group2)

	1B	1C	2A	2B	2C	2D	2E	Arm3	Overall
	30µg R0.6C-AIOH+15µg Matrix-M and 12.5µg Pfs230D1-EPA+25µg Matrix-M	Comparator Vaccine (Rabies) and normal saline	100µg R0.6C-AIOH+50µg Matrix-M and normal saline	100µg ProC6C-AIOH+50µg Matrix-M and normal saline	40µg Pfs230D1-EPA+50µg Matrix-M and normal saline	100µg R0.6C-AIOH+25µg Matrix-M and 40µg Pfs230D1-EPA+ 25µg Matrix-M (Pfs230D1-EPA)	Comparator Vaccine (Rabies) and normal saline	40µg Pfs230D1-EPA+50µg Matrix-M	
	N = 19 ¹	N = 19 ¹	N = 62 ¹	N = 64 ¹	N = 88 ¹	N = 61 ¹	N = 56 ¹	N = 29 ¹	N = 398 ¹
Abdominal pain	0 (0%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	1 (33%)	1 (33%)	0 (0%)	3 (100%)
Abscess	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	2 (100%)
Aches	0 (0%)	0 (0%)	1 (50%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	0 (0%)	2 (100%)
Acute Malaria	2 (2.4%)	6 (7.2%)	11 (13%)	16 (19%)	14 (17%)	12 (14%)	16 (19%)	6 (7.2%)	83 (100%)
Anaemia	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)
Anorexia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)
Back pain	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)
Chest Pain	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	1 (50%)	0 (0%)	2 (100%)
Conjunctival hyperaemia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	1 (100%)
Diarrhoea	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	1 (100%)
Dizziness	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	1 (100%)
Elevated ALT	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	2 (100%)
Elevated creatinine	0 (0%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	2 (100%)
Epigastralgia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)
Genital infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	1 (100%)
Headaches	1 (2.1%)	2 (4.2%)	5 (10%)	5 (10%)	14 (29%)	11 (23%)	7 (15%)	3 (6.3%)	48 (100%)
Hemoglobin increased	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	1 (100%)
Inguinal hernia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)
Injection site movement impairment	1 (33%)	0 (0%)	1 (33%)	1 (33%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)
Injection site pain	5 (5.7%)	1 (1.1%)	17 (19%)	15 (17%)	21 (24%)	14 (16%)	6 (6.8%)	9 (10%)	88 (100%)

[illegible]